Global Oncology-based In-Vivo CRO Market is estimated to grow to US$ 2.9 Billion by 2033, with a CAGR of 10.9%, as per FMI’s analysis

The global oncology-based in-vivo CRO market is worth US$ 1.1 Billion as of now and is expected to reach US$ 2.9 Billion by the year 2033 at a notable CAGR of 10.9% between 2023 and 2033.

The WHO states that as of the year 2020, 19.3 Million novel cases of cancer were reported along with 10 Million fatalities. This alarming figure has been provoking the key participants to get into excessive research regarding oncology-based in-vivo CRO.

These days the pharmaceutical companies are outsourcing their research activities to the CRO services owing to increasing focus on the aspects that happen to be all the more important; that too, with cost-effectiveness.

Get Your Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-16431

The companies are found outsourcing activities ranging between basic research and efficacy tests in the animal models and also late-stage clinical trials.

The Tufts Center for study of Drug Development (CSDD) has conducted research, as per which over 75% of the pharmaceutical companies do agree that the CROs are much more time-efficient as compared to internal teams.

Future Market Insights has walked through these facts with future prospects in its latest market study entitled ‘Oncology-based In-Vivo CRO Market’.

“With economic efficiency offered by the CROs, the global oncology-based in-vivo CRO market is expected to grow on a robust note in the forecast period”, says an analyst from Future Market Insights.

Key Takeaways from Oncology-based In-Vivo CRO Market:

• North America holds the largest market share with cancer therapy being increasingly adopted all over the US.
• Europe holds the second-largest market share with the UK expected to be the flag bearer.
• The Asia-Pacific is expected to grow on the back of extensive research being conducted in this regard. For instance – Crown Bioscience, in October 2020, did expand its capacity of the Asia-Pacific by opening a new-fangled oncology-based research facility at Zhongshan (China).

Our Analyst Is Available To Help You With Any Inquiries Reach Out Anytime! https://www.futuremarketinsights.com/ask-question/rep-gb-16431

Competitive Analysis:

• Evotech SE, in November 2020, entered into partnership with Rappta Therapeutics for developing a petite molecule reactivating PP2A that does suppress response regarding multiple oncogenic signaling pathways holding the responsibility of cancer progression.
• Evotec, in April 2021, entered into partnership with Kazia Therapeutics to develop and commercialize its oncology project ‘EVT801’. The company’s objective is that of conducting phase I trial under Kazia’s sponsorship.
• Evotec SE, in April 2021, did invest in OxVax (an immune-oncology company that has its base in Oxford University’s research enabling creation of next gen cancer vaccines) with purpose of outperforming the methods that exist. The vaccine trains the body to target tumors and get away with them.
• Crown Bioscience, in October 2021, did launch 3D ex Vivo Patient Tissue Platform that makes use of the patient’s tumor tissue extracted from surgical resections, biopsies, and ascites or samples of pleural effusion and processed for preserving tumor microenvironment.
• Charles River Laboratories, in October 2021, got acquired by Jackson Laboratory (better known as Jackson Laboratory Japan). It does provide access to resources and animal models, so as to help researchers make scientific advancements as well as breakthrough in development of drugs.
• Researchers in Jackson Laboratory, in July 2022, successfully demonstrated responses of patients with BRCA mutations, thereby coming up with resistance against platinum-based therapy other than BRCA1 promoter methylation. The team made use of PDX (patient-derived xenograft) mouse models, patient data, and engineered cancer cell lines. They also came up with an algorithm for ovarian cancer and TNBC that potentially responds to chemotherapy.
• The Jackson Laboratory team, in May 2022, did deploy ML for capturing accurate insights regarding cancer patients and interpret the images of tumor quicker and all the more accurately, thereby providing probability of more focused treatment without requirement for extra testing.
• eTheRNA Immunotherapies, in March 2022, came up with a novel LNP (Lipid Nanoparticle) formulation service for supporting discovery as well as early pre-clinical development of RNA-based vaccines and therapeutics.
• Moderna, Inc., in October 2022, along with Merck, did report that the latter had started developing PCV (personalized cancer vaccine) called mRNA-4157/V940 as per existent Collaboration and License Agreement.

Delivering Excellence Through Customization: Lessons from Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16431

What does the Report say?

• The research study is based on indication (blood cancer (syngeneic model, PDX (patient derived xenograft), and xenograft), solid tumors (syngeneic model, patient derived xenograft (PDX), and xenograft), and other indications (syngeneic model, PDX (patient derived xenograft), and xenograft)).
• With growing incidences of oncology-based cases coupled with need of developing new drugs to treat cancer patients, the global oncology-based in-vivo CRO market is expected to go great guns in the forecast period.

Key Companies Profiled:

• The Jackson Laboratory
• EVOTEC
• WuXi AppTec
• Toxicon Inc.
• Crown Bioscience
• Taconic Biosciences
• Eurofins Scientific
• ICON Plc
• Charles River Laboratory
• Covance
• Others

Gain Immediate Access to Detailed Market Insights: Purchase Now! https://www.futuremarketinsights.com/checkout/16431

Key Segments Covered in Oncology-based in-vivo CRO Industry Survey:

By Indication:

• Blood Cancer
  • Syngeneic Model
  • Patient Derived Xenograft (PDX)
  • Xenograft
• Solid Tumors
  • Syngeneic Model
  • Patient Derived Xenograft (PDX)
  • Xenograft
• Other Indications
  • Syngeneic Model
  • Patient Derived Xenograft (PDX)
  • Xenograft

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube